scientific programme
28
Monday, 23 June 2014
JS-01-002
Identification of chromosomal segments and
individual genes critical for schizophrenia
in mouse models of 22q11.2 copy number
variants
Noboru Hiroi, USA
JS-01-003
Intermediate phenotype studies in schizo-
phrenia
Ryota Hashimoto, Japan
K. Ohi, H. Yamamori, Y. Yasuda, M. Fujimoto,
S. Umeda-Yano, M. Takeda
JS-01-004
The research and development of aripiprazole
Tetsuro Kikuchi, Japan
Learning Objectives:
This symposium pro-
vides a broad update on the pharmacogentics
of schizophrenia.
SW-01
SCIENTIFIC WORKSHOP
10:00–11:00
Room 13
The pitfalls, problems using gene knock-
out animals in neuropsychopharmacology
SW-01-001
Should we do away with the knockout
mouse?
Caitlin McOmish, Australia
Learning Objectives:
This workshop will alert
delegates to the benefits and potential pitfalls
in using genetically modified animals as model
for neuropsychopharmacological and psychia-
try research.
EW-02
EDUCATIONAL WORKSHOP
11:10–12:10
Room 13
The use of psychotropic drugs during
pregnancy and breast feeding
Marie-Josée Poulin, Canada
Learning Objectives:
This workshop will edu-
cate delegates on the problems and solutions
for treating women with psychotropic drugs
during pregnancy.
PL-02
PLENARY LECTURE
14:00–14:45
Plenary Hall A
Track: Discovery research
Nobel Lecture–Structural insights into G-
protein coupled receptor signaling
Brian Kobilka, USA
Learning Objectives:
Delegates attending this
presentation would have an improved insight
into how drugs used to treat a wide range of
psychiatric disorders work.
S-06
SYMPOSIUM
15:00–17:00
Ballroom A
Track: Translational
Topic: Depression (A)
Emerging neuromechanisms for the treat-
ment of depression: Insights from animal
and human studies
Chair:
Athina Markou, USA
Co-Chair: Ronald Duman, USA
S-06-001
Role of mTOR signaling and synaptoge-
nesis in the response to rapid acting anti-
depressants
Ronald Duman, USA
S-06-002
Resilence and susceptibility to stress: Pre-
dictors of response to antidepressants and
ketamine
Athina Markou, USA
A. Der-Avakian
S-06-003
Neuropeptide receptors as targets for drug
discovery for the treatment of depression
Shigeyuki Chaki, Japan
S-06-004
Rewiring faulty circuits: The promise of deep
brain stimulation for severe major depression
Thomas Schlaepfer, Germany
Learning Objectives:
Treatment resistant de-
pression is a significant clinical problem; this
symposium will give an update on efforts to
identify potential new drug treatment targets
for the disorder.
